다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Seminars in cancer biology, v.55, 2019년, pp.106 - 119
Zhan, Tianzuo (German Cancer Research Center (DKFZ), Division Signaling and Functional Genomics, and Heidelberg University, Department Cell and Molecular Biology, Faculty of Medicine Mannheim) , Rindtorff, Niklas (German Cancer Research Center (DKFZ), Division Signaling and Functional Genomics, and Heidelberg University, Department Cell and Molecular Biology, Faculty of Medicine Mannheim) , Betge, Johannes (German Cancer Research Center (DKFZ), Division Signaling and Functional Genomics, and Heidelberg University, Department Cell and Molecular Biology, Faculty of Medicine Mannheim) , Ebert, Matthias P. (Heidelberg University, Department of Internal Medicine II, Medical Faculty Mannheim) , Boutros, Michael (German Cancer Research Center (DKFZ), Division Signaling and Functional Genomics, and Heidelberg University, Department Cell and Molecular Biology, Faculty of Medicine Mannheim)
AI-Helper
Abstract CRISPR/Cas9 has become a powerful method for making changes to the genome of many organisms. First discovered in bacteria as part of an adaptive immune system, CRISPR/Cas9 and modified versions have found a widespread use to engineer genomes and to activate or to repress the expression of ...
CA. Cancer J. Clin. Torre 65 87 2015 10.3322/caac.21262 Global cancer statistics, 2012
N. Engl. J. Med. Kantarjian 346 645 2002 10.1056/NEJMoa011573 Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia
N. Engl. J. Med. Cunningham 351 337 2004 10.1056/NEJMoa033025 Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
Nat. Genet. Chang 45 1113 2013 10.1038/ng.2764 The cancer genome atlas pan-cancer analysis project
Nature T.I.C.G. International Cancer Genome Consortium 464 993 2010 10.1038/nature08987 International network of cancer genome projects
Cell Garraway 153 17 2013 10.1016/j.cell.2013.03.002 Lessons from the cancer genome
Nat. Rev. Mol. Cell Biol. Joung 14 49 2012 10.1038/nrm3486 TALENs: a widely applicable technology for targeted genome editing
Nat. Rev. Genet. Urnov 11 636 2010 10.1038/nrg2842 Genome editing with engineered zinc finger nucleases
Science. Cong 339 819 2013 10.1126/science.1231143 Multiplex genome engineering using CRISPR/Cas systems
Science. Mali 339 823 2013 10.1126/science.1232033 RNA-guided human genome engineering via Cas9
J. Bacteriol. Ishino 169 5429 1987 10.1128/jb.169.12.5429-5433.1987 Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product
ACS Chem. Biol. Kampmann 2017 CRISPRi and CRISPRa screens in mammalian cells for precision biology and medicine
Microbiology Bolotin 151 2551 2005 10.1099/mic.0.28048-0 Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin
Microbiology Pourcel 151 653 2005 10.1099/mic.0.27437-0 CRISPR elements in Yersinia pestis acquire new repeats by preferential uptake of bacteriophage DNA, and provide additional tools for evolutionary studies
J. Mol. Evol. Mojica 60 174 2005 10.1007/s00239-004-0046-3 Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements
Science Barrangou 315 1709 2007 10.1126/science.1138140 CRISPR provides acquired resistance against viruses in prokaryotes
Nature. Deltcheva 471 602 2011 10.1038/nature09886 CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III
Proc. Natl. Acad. Sci. U. S. A. Gasiunas 109 2012 10.1073/pnas.1208507109 Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria
Science Jinek 337 816 2012 10.1126/science.1225829 A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity
J. Bacteriol. Deveau 190 1390 2008 10.1128/JB.01412-07 Phage response to CRISPR-encoded resistance in Streptococcus thermophilus
Nature. Sternberg 507 62 2014 10.1038/nature13011 DNA interrogation by the CRISPR RNA-guided endonuclease Cas9
J. Bacteriol. Deveau 190 1390 2008 10.1128/JB.01412-07 Phage response to CRISPR-encoded resistance in Streptococcus thermophilus
Cell. Chen 155 1479 2013 10.1016/j.cell.2013.12.001 Dynamic imaging of genomic loci in living human cells by an optimized CRISPR/Cas system
Cell Zetsche 163 759 2015 10.1016/j.cell.2015.09.038 Cpf1 Is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system
Science Abudayyeh 353 2016 10.1126/science.aaf5573 C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector
Mol. Cell. Smargon 65 618 2017 10.1016/j.molcel.2016.12.023 Cas13b Is a type VI-B CRISPR-associated RNA-guided RNase differentially regulated by accessory proteins Csx27 and Csx28
Cell Qi 152 1173 2013 10.1016/j.cell.2013.02.022 Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression
Cell Gilbert 1 2013 CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes
Nat. Methods Thakore 12 1143 2015 10.1038/nmeth.3630 Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements
Nat. Methods Maeder 10 977 2013 10.1038/nmeth.2598 CRISPR RNA-guided activation of endogenous human genes
Nat. Methods Chavez 12 326 2015 10.1038/nmeth.3312 Highly efficient Cas9-mediated transcriptional programming
Cell Tanenbaum 159 635 2014 10.1016/j.cell.2014.09.039 A protein-tagging system for signal amplification in gene expression and fluorescence imaging
Nature Konermann 517 583 2014 10.1038/nature14136 Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
Nat. Methods Chavez 13 563 2016 10.1038/nmeth.3871 Comparison of Cas9 activators in multiple species
Biol. Open McDonald 5 866 2016 10.1242/bio.019067 Reprogrammable CRISPR/Cas9-based system for inducing site-specific DNA methylation
Nucleic Acids Res. Vojta 44 5615 2016 10.1093/nar/gkw159 Repurposing the CRISPR-Cas9 system for targeted DNA methylation
Nucleic Acids Res. Stepper 45 1703 2017 10.1093/nar/gkw1112 Efficient targeted DNA methylation with chimeric dCas9-Dnmt3a-Dnmt3L methyltransferase
Cell Discov. Xu 2 16009 2016 10.1038/celldisc.2016.9 A CRISPR-based approach for targeted DNA demethylation
Nat. Biotechnol. Hilton 33 510 2015 10.1038/nbt.3199 Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers
Nature Komor 533 420 2016 10.1038/nature17946 Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage
Nat. Methods Kuscu 14 710 2017 10.1038/nmeth.4327 CRISPR-STOP: gene silencing through base-editing-induced nonsense mutations
Science Nishida 353 2016 10.1126/science.aaf8729 Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems
Nat. Methods Ma 13 1029 2016 10.1038/nmeth.4027 Targeted AID-mediated mutagenesis (TAM) enables efficient genomic diversification in mammalian cells
Nat. Methods Hess 13 1036 2016 10.1038/nmeth.4038 Directed evolution using dCas9-targeted somatic hypermutation in mammalian cells
Genes Genom. Genet. Hart 7 2719 2017 10.1534/g3.117.041277 Evaluation and design of genome-wide CRISPR/SpCas9 knockout screens
Nat. Biotechnol. Doench 2016 10.1038/nbt.3437 Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9
Nat. Biotechnol. Tsai 33 187 2014 10.1038/nbt.3117 GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
Nat. Methods Kim 12 237 2015 10.1038/nmeth.3284 Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in human cells
Nat. Methods Tsai 14 607 2017 10.1038/nmeth.4278 CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR-Cas9 nuclease off-targets
Nat. Methods Meier 14 831 2017 10.1038/nmeth.4423 GUIDES: sgRNA design for loss-of-function screens
Genome Biol. Heigwer 17 55 2016 10.1186/s13059-016-0915-2 CRISPR library designer (CLD): software for multispecies design of single guide RNA libraries
Nat. Biotechnol. Evers 34 631 2016 10.1038/nbt.3536 CRISPR knockout screening outperforms shRNA and CRISPRi in identifying essential genes
Cancer Discov. Munoz 6 900 2016 10.1158/2159-8290.CD-16-0178 CRISPR screens provide a comprehensive assessment of cancer vulnerabilities but generate false-positive hits for highly amplified genomic regions
Cell Hart 163 1515 2015 10.1016/j.cell.2015.11.015 High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities
Cancer Discov. Aguirre 6 914 2016 10.1158/2159-8290.CD-16-0154 Genomic copy number dictates a gene-independent cell response to CRISPR/Cas9 targeting
Nat. Genet. Meyers 49 1779 2017 10.1038/ng.3984 Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells
Cell Rep. Tzelepis 17 1193 2016 10.1016/j.celrep.2016.09.079 A CRISPR dropout screen identifies genetic vulnerabilities and therapeutic targets in acute myeloid leukemia
Mol. Syst. Biol. Rauscher 14 e7656 2018 10.15252/msb.20177656 Toward an integrated map of genetic interactions in cancer cells
Nat. Biotechnol. Shi 33 661 2015 10.1038/nbt.3235 Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains
Nature Erb 543 270 2017 10.1038/nature21688 Transcription control by the ENL YEATS domain in acute leukaemia
Crit. Rev. Biochem. Mol. Biol. Zhan 1 2015 Towards a compendium of essential genes - from model organisms to synthetic lethality in cancer cells
N. Engl. J. Med. Robson 377 523 2017 10.1056/NEJMoa1706450 Olaparib for metastatic breast cancer in patients with a germline BRCA mutation
Nat. Med. Steinhart 23 60 2017 10.1038/nm.4219 Genome-wide CRISPR screens reveal a Wnt-FZD5 signaling circuit as a druggable vulnerability of RNF43-mutant pancreatic tumors
Cell. Wang 168 890 2017 10.1016/j.cell.2017.01.013 Gene essentiality profiling reveals gene networks and synthetic lethal interactions with oncogenic ras
Nat. Rev. Genet. Shalem 16 299 2015 10.1038/nrg3899 High-throughput functional genomics using CRISPR-Cas9
Mol. Cell. Ruiz 62 307 2016 10.1016/j.molcel.2016.03.006 A genome-wide CRISPR screen identifies CDC25A as a determinant of sensitivity to ATR inhibitors
Elife. Krall 6 2017 KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer
Blood Gayle 129 1768 2017 10.1182/blood-2016-09-736892 Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma
Nat. Biotechnol. Han 35 463 2017 10.1038/nbt.3834 Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions
Nat. Methods Shen 14 573 2017 10.1038/nmeth.4225 Combinatorial CRISPR-Cas9 screens for de novo mapping of genetic interactions
Cell Jaitin 167 1883 2016 10.1016/j.cell.2016.11.039 Dissecting immune circuits by linking CRISPR-Pooled screens with single-cell RNA-Seq
Cell Dixit 167 1853 2016 10.1016/j.cell.2016.11.038 Perturb-Seq: dissecting molecular circuits with scalable single-cell RNA profiling of pooled genetic screens
Cell Adamson 167 1867 2016 10.1016/j.cell.2016.11.048 A multiplexed single-cell CRISPR screening platform enables systematic dissection of the unfolded protein response
Nat. Methods Datlinger 14 297 2017 10.1038/nmeth.4177 Pooled CRISPR screening with single-cell transcriptome readout
Nat. Med. Huarte 21 1253 2015 10.1038/nm.3981 The emerging role of lncRNAs in cancer
Science Sanjana 353 1545 2016 10.1126/science.aaf7613 High-resolution interrogation of functional elements in the noncoding genome
Nat. Biotechnol. Korkmaz 34 192 2016 10.1038/nbt.3450 Functional genetic screens for enhancer elements in the human genome using CRISPR-Cas9
Nat. Biotechnol. Zhu 34 1279 2016 10.1038/nbt.3715 Genome-scale deletion screening of human long non-coding RNAs using a paired-guide RNA CRISPR-Cas9 library
Science Liu 355 2017 10.1126/science.aah7111 CRISPRi-based genome-scale identification of functional long noncoding RNA loci in human cells
Cancer Cell Yan 28 529 2015 10.1016/j.ccell.2015.09.006 Comprehensive genomic characterization of Long non-coding RNAs across human cancers
Nature Joung 548 343 2017 10.1038/nature23451 Genome-scale activation screen identifies a lncRNA locus regulating a gene neighbourhood
Nucleic Acids Res. Goyal 45 2016 Challenges of CRISPR/Cas9 applications for long non-coding RNA genes
Cell Clevers 165 1586 2016 10.1016/j.cell.2016.05.082 Modeling development and disease with organoids
Cell Stem Cell Schwank 13 653 2013 10.1016/j.stem.2013.11.002 Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients
Nature Drost 521 43 2015 10.1038/nature14415 Sequential cancer mutations in cultured human intestinal stem cells
Nat. Med. Matano 21 256 2015 10.1038/nm.3802 Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids
Science Drost 3130 2017 Use of CRISPR-modified human stem cell organoids to study the origin od mutational signatures in cancer
Nature Tao 2016 10.1038/nature19799 Frizzled proteins are colonic epithelial receptors for C. difficile toxin B
Am. J. Physiol. Gastrointest. Liver Physiol. Driehuis 2017 10.1152/ajpgi.00410.2016 CRISPR/Cas 9 genome editing and its applications in organoids
Nature Xue 514 380 2014 10.1038/nature13589 CRISPR-mediated direct mutation of cancer genes in the mouse liver
Nat. Commun. Maresch 7 10770 2016 10.1038/ncomms10770 Multiplexed pancreatic genome engineering and cancer induction by transfection-based CRISPR/Cas9 delivery in mice
Nat. Commun. Zuckermann 6 7391 2015 10.1038/ncomms8391 Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling
Cancer Lett. Luo 356 347 2015 10.1016/j.canlet.2014.10.045 Adeno-associated virus-mediated cancer gene therapy: current status
Mol. Ther. Zincarelli 16 1073 2008 10.1038/mt.2008.76 Analysis of AAV serotypes 1-9 mediated Gene expression and tropism in mice after systemic injection
Biotechnol. J. Senís 9 1402 2014 10.1002/biot.201400046 CRISPR/Cas9-mediated genome engineering: an adeno-associated viral (AAV) vector toolbox
Nat. Commun. Yu 8 14716 2017 10.1038/ncomms14716 Nrl knockdown by AAV-delivered CRISPR/Cas9 prevents retinal degeneration in mice
J. Clin. Invest. Yang 127 2719 2017 10.1172/JCI92087 CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington’s disease
Nat. Biotechnol. Yang 34 334 2016 10.1038/nbt.3469 A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice
Nat. Commun. Bengtsson 8 14454 2017 10.1038/ncomms14454 Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy
Science Tabebordbar 351 407 2016 10.1126/science.aad5177 In vivo gene editing in dystrophic mouse muscle and muscle stem cells
Nat. Methods Chew 13 868 2016 10.1038/nmeth.3993 A multifunctional AAV-CRISPR-Cas9 and its host response
Adv. Drug Deliv. Rev. Mehnert 64 83 2012 10.1016/j.addr.2012.09.021 Solid lipid nanoparticles: production, characterization and applications
Nature Pardi 543 248 2017 10.1038/nature21428 Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination
Cell Rep. Finn 22 2227 2018 10.1016/j.celrep.2018.02.014 A single administration of CRISPR/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing
Cell Res. Jiang 27 440 2017 10.1038/cr.2017.16 A non-viral CRISPR/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 in vivo
Angew. Chem. Int. Ed. Miller 56 1059 2017 10.1002/anie.201610209 Non-viral CRISPR/Cas gene editing in vitro and in vivo enabled by synthetic nanoparticle co-delivery of Cas9 mRNA and sgRNA
Nat. Biomed. Eng. Lee 1 889 2017 10.1038/s41551-017-0137-2 Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair
Cancer Treat. Rev. Barata 50 35 2016 10.1016/j.ctrv.2016.08.004 RNA-targeted therapeutics in cancer clinical trials: current status and future directions
Cell Chen 160 1246 2015 10.1016/j.cell.2015.02.038 Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis
Gastroenterology Song 152 1161 2017 10.1053/j.gastro.2016.12.002 Genome-wide CRISPR screen identifies regulators of mitogen-activated protein kinase as suppressors of liver tumors in mice
Nat. Biotechnol. Roper 35 569 2017 10.1038/nbt.3836 In vivo genome editing and organoid transplantation models of colorectal cancer and metastasis
Proc. Natl. Acad. Sci. Weber 112 13982 2015 10.1073/pnas.1512392112 CRISPR/Cas9 somatic multiplex-mutagenesis for high-throughput functional cancer genomics in mice
Cell Platt 159 440 2014 10.1016/j.cell.2014.09.014 CRISPR-Cas9 knockin mice for genome editing and cancer modeling
Nat. Neurosci. Chow 20 1329 2017 10.1038/nn.4620 AAV-mediated direct in vivo CRISPR screen identifies functional suppressors in glioblastoma
Gene Wirth 525 162 2013 10.1016/j.gene.2013.03.137 History of gene therapy
Nature Hirsch 551 327 2017 10.1038/nature24487 Regeneration of the entire human epidermis using transgenic stem cells
N. Engl. J. Med. Mendell 377 1713 2017 10.1056/NEJMoa1706198 Single-dose gene-replacement therapy for spinal muscular atrophy
N. Engl. J. Med. Rangarajan 377 2519 2017 10.1056/NEJMoa1708483 AAV5-Factor VIII gene transfer in severe hemophilia A
Lancet Russell 390 849 2017 10.1016/S0140-6736(17)31868-8 Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial
N. Engl. J. Med. Tebas 370 901 2014 10.1056/NEJMoa1300662 Gene editing of CCR5 in eutologous CD4 T cells of persons infected with HIV
Nat. Med. Cornu 23 415 2017 10.1038/nm.4313 Refining strategies to translate genome editing to the clinic
Nature Cyranoski 539 479 2016 10.1038/nature.2016.20988 CRISPR gene-editing tested in a person for the first time
Proc. Natl. Acad. Sci. Iwai 99 12293 2002 10.1073/pnas.192461099 Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
N. Engl. J. Med. Reck 375 1823 2016 10.1056/NEJMoa1606774 Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer
Nature Eyquem 543 113 2017 10.1038/nature21405 Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Nat. Methods Heigwer 11 122 2014 10.1038/nmeth.2812 E-CRISP: fast CRISPR target site identification
Nat. Biotechnol. Hsu 31 827 2013 10.1038/nbt.2647 DNA targeting specificity of RNA-guided Cas9 nucleases
Nucleic Acids Res. Labun 44 W272 2016 10.1093/nar/gkw398 CHOPCHOP v2: a web tool for the next generation of CRISPR genome engineering
Nat. Biotechnol. MacPherson 33 805 2015 10.1038/nbt.3291 Flexible guide-RNA design for CRISPR applications using protospacer workbench
Nat. Methods Moreno-Mateos 12 982 2015 10.1038/nmeth.3543 CRISPRscan: designing highly efficient sgRNAs for CRISPR-Cas9 targeting in vivo
Nat. Methods Chari 12 823 2015 10.1038/nmeth.3473 Unraveling CRISPR-Cas9 genome engineering parameters via a library-on-library approach
Bioinformatics Winter 32 632 2016 10.1093/bioinformatics/btv617 caRpools: an R package for exploratory data analysis and documentation of pooled CRISPR/Cas9 screens
Genome Biol. Li 16 281 2015 10.1186/s13059-015-0843-6 Quality control, modeling, and visualization of CRISPR screens with MAGeCK-VISPR
Bioinformatics Yu 32 260 2016 10.1093/bioinformatics/btv556 ScreenBEAM: a novel meta-analysis algorithm for functional genomics screens via Bayesian hierarchical modeling
bioRxiv Winter 109967 2017 CRISPRAnalyzeR: Interactive analysis, annotation and documentation of pooled CRISPR screens
해당 논문의 주제분야에서 활용도가 높은 상위 5개 콘텐츠를 보여줍니다.
더보기 버튼을 클릭하시면 더 많은 관련자료를 살펴볼 수 있습니다.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
저자가 APC(Article Processing Charge)를 지불한 논문에 한하여 자유로운 이용이 가능한, hybrid 저널에 출판된 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.